BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- BioMimetix JV, LLC
- Target Recruit Count
- 27
- Registration Number
- NCT06620029
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- BioMimetix JV, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT05491447
- Locations
- 🇺🇸
Cahaba Dermatology & Skin Health Center, Birmingham, Alabama, United States
🇺🇸Lenus Research, Sweetwater, Florida, United States
🇺🇸Revival Research Institute, LLC, Troy, Michigan, United States
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- BioMimetix JV, LLC
- Registration Number
- NCT04607642
Evaluation of Topical Application of BMX-010 in Subjects With Rosacea
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- BioMimetix JV, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT03756389
- Locations
- 🇺🇸
Colorado Skin Care, Englewood, Colorado, United States
Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- BioMimetix JV, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT03752242
- Locations
- 🇺🇸
Colorado Skin Care, Englewood, Colorado, United States
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- BioMimetix JV, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT03608020
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Duke Cancer Institute, Durham, North Carolina, United States
Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- BioMimetix JV, LLC
- Target Recruit Count
- 139
- Registration Number
- NCT03381625
- Locations
- 🇺🇸
Encino Research Center, Encino, California, United States
🇺🇸AboutSkin Dermatology & DermSurgery, Greenwood Village, Colorado, United States
🇺🇸Apex Dermatology, Denver, Colorado, United States
A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- BioMimetix JV, LLC
- Target Recruit Count
- 29
- Registration Number
- NCT02990468
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸University of Florida- Gainesville, Gainesville, Florida, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- BioMimetix JV, LLC
- Target Recruit Count
- 160
- Registration Number
- NCT02655601
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸Duke Cancer Institute, Durham, North Carolina, United States